Breaking News, Collaborations & Alliances

Lilly, Sigilon Partner for Diabetes

The collaboration is to develop encapsulated cell therapies for the potential treatment of type 1 diabetes

Eli Lilly and Company and Sigilon Therapeutics have entered a global collaboration to develop encapsulated cell therapies for the potential treatment of type 1 diabetes.    Sigilon is a privately-held biopharmaceutical company that is focused on discovering and developing “living therapeutics” with its Afibromer™ technology product platform. Lilly is a global biopharmaceutical company and a worldwide leader in diabetes care, offering a wide range of therapies and a strong com...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters